N Bhutiani1, J E Schucht1, K R Miller1, Stephen A McClave2. 1. Department of Surgery, Division of Trauma and Critical Care, University of Louisville, Louisville, KY, USA. 2. Department of Medicine, Division of Gastroenterology, University of Louisville, 550 S. Jackson St., Ambulatory Care Building 3nd Floor, Louisville, KY, 40202, USA. Samccl01@louisville.edu.
Abstract
PURPOSE OF REVIEW: Fecal microbial transplantation (FMT) has become established as an effective therapeutic modality in the treatment of antibiotic-refractory recurrent Clostridium difficile colitis. A number of formulations and methods of delivery of FMT are currently available, each with distinct advantages. This review aims to review donor and patient selection for FMT as well as procedural aspects of FMT to help guide clinical practice. RECENT FINDINGS: FMT can be obtained in fresh, frozen, lyophilized, and capsule-based formulations for delivery by oral ingestion, nasoenteric tube, colonoscopy, or enema (depending on the formulation used). Choosing the optimal method relies heavily on patient-related factors, including underlying pathology and severity of illness. As potential applications for FMT expand, careful donor screening and patient selection are critical to minimizing risk to patients and physicians. FMT represents an excellent therapeutic option for treatment of recurrent Clostridium difficile colitis and holds promise as a possible treatment modality in a variety of other conditions. The wide array of delivery methods allows for its application in various disease states in both the inpatient and outpatient setting.
PURPOSE OF REVIEW: Fecal microbial transplantation (FMT) has become established as an effective therapeutic modality in the treatment of antibiotic-refractory recurrent Clostridium difficilecolitis. A number of formulations and methods of delivery of FMT are currently available, each with distinct advantages. This review aims to review donor and patient selection for FMT as well as procedural aspects of FMT to help guide clinical practice. RECENT FINDINGS: FMT can be obtained in fresh, frozen, lyophilized, and capsule-based formulations for delivery by oral ingestion, nasoenteric tube, colonoscopy, or enema (depending on the formulation used). Choosing the optimal method relies heavily on patient-related factors, including underlying pathology and severity of illness. As potential applications for FMT expand, careful donor screening and patient selection are critical to minimizing risk to patients and physicians. FMT represents an excellent therapeutic option for treatment of recurrent Clostridium difficilecolitis and holds promise as a possible treatment modality in a variety of other conditions. The wide array of delivery methods allows for its application in various disease states in both the inpatient and outpatient setting.
Authors: Michael J Morowitz; Trissa Babrowski; Erica M Carlisle; Andrea Olivas; Kathleen S Romanowski; John B Seal; Donald C Liu; John C Alverdy Journal: Ann Surg Date: 2011-06 Impact factor: 12.969
Authors: Jennifer Defazio; Irma D Fleming; Baddr Shakhsheer; Olga Zaborina; John C Alverdy Journal: Surg Clin North Am Date: 2014-10-07 Impact factor: 2.741
Authors: Ilan Youngster; George H Russell; Christina Pindar; Tomer Ziv-Baran; Jenny Sauk; Elizabeth L Hohmann Journal: JAMA Date: 2014-11-05 Impact factor: 56.272
Authors: Baddr A Shakhsheer; Luke A Versten; James N Luo; Jennifer R Defazio; Robin Klabbers; Scott Christley; Alexander Zaborin; Kristina L Guyton; Monika Krezalek; Daniel P Smith; Nadim J Ajami; Joseph F Petrosino; Irma D Fleming; Natalia Belogortseva; Olga Zaborina; John C Alverdy Journal: J Gastrointest Surg Date: 2016-08-16 Impact factor: 3.452
Authors: S Banerjee; G Sindberg; F Wang; J Meng; U Sharma; L Zhang; P Dauer; C Chen; J Dalluge; T Johnson; S Roy Journal: Mucosal Immunol Date: 2016-02-24 Impact factor: 7.313
Authors: Emily L Gulliver; Remy B Young; Michelle Chonwerawong; Gemma L D'Adamo; Tamblyn Thomason; James T Widdop; Emily L Rutten; Vanessa Rossetto Marcelino; Robert V Bryant; Samuel P Costello; Claire L O'Brien; Georgina L Hold; Edward M Giles; Samuel C Forster Journal: Aliment Pharmacol Ther Date: 2022-05-24 Impact factor: 9.524